Medidata has announced that its cloud technology has been selected by Biogen to support future clinical trials. Biogen will increase its adoption of Medidata Rave®— a solution for capturing, managing and reporting patient data—and Medidata TSDV, a solution that maximizes the efficiency of costly data verification.
The agreement expands an existing relationship to use Rave and TSDV across Biogen’s diverse clinical development portfolio, which includes potential therapies for neurological, autoimmune and rare diseases.
“Medidata is thrilled to provide Biogen with next-generation technology to help accelerate scientific innovation,” said Medidata’s CEO Tarek Sherif. “We look forward to expanding this relationship and contributing to Biogen’s efforts to pursue novel treatments as they seek to improve the standard of care for patients living with serious unmet medical conditions.”
The expanded use of Medidata’s technology platform aims to enhance study planning and execution, site performance and data quality across Biogen’s clinical development programs.